In addition, formononetin treatment downregulated p-AKT in several other types of cancer cells, including U266 multiple myeloma (Wu et al., 2016), Hela cervical cancer (Jin et al., 2014), PC-3 prostate cancer (Zhang et al., 2014), and U2OS osteosarcoma cells (Hu and Xiao, 2015). Here, AKT1 is linked to AL amyloidosis.